Nuevolution Announces Formation of Strong Scientific Advisory Panel
Published: Mar 13, 2013
In June 2012, Nuevolution announced the closing of a new financing round, and the plans to initiate internal drug discovery efforts. Since then, Nuevolution has prioritized more than 30 high-value challenging targets for screening, which has been initiated. The target prioritization and further program decisions have been made in close collaboration with the newly appointed advisors.
Professor Sir Marc Feldmann, Kennedy Institute, UK. Dr. Feldmann is a world-renowned scientist within immunology and a special interest in the fields of autoimmune diseases and the roles of cytokines. He is recipient of numerous honors and awards over the years and has pioneered the work on the development of antibodies against TNFa for the treatment of RA.
Professor Dr. Gordon B. Mills, MD Anderson Cancer Center, US. Dr. Mills is a world-leading scientist within oncology and professor and chair in the Department of Systems Biology in the Division of Cancer Medicine at the MD Anderson Cancer Center, where he holds the Olga Keith Wiess Distinguished University Chair in Cancer Medicine. Dr. Mills is co-director of the Sheikh Khalifa bin Zayed Al Nahyan Institute for Personalized Cancer Therapy and director Kleberg Center for Molecular Markers. He also serves as advisor for pre-clinical and clinical oncology studies supporting numerous pharmaceutical- and biotechnology companies.
Dr. Alan Collis, formerly Novartis and Aventis, US. Dr. Collis has 25 years of industry experience. He has a very strong track-record within chemistry, DMPK studies and pre-clinical candidate development. He has served as head of section within oncology at Novartis and as a central member of their Oncology and Exploratory Chemistry leadership team. At Aventis he served at their Review Board involved with recommendations from target selection through to phase IIb initiation within inflammation and CNS diseases.
”We are obviously delighted to receive support from such a strong and experienced advisory team to help us leverage our Chemetics® technology platform and plan and promote our own pipeline” said Thomas Franch, CSO of Nuevolution. “We look forward to working with Marc, Gordon and Alan and we are confident that they will help accelerate our discovery projects and provide substantial value to our programs.
Nuevolution is a leading small molecule lead discovery company founded in 2001 and based in Copenhagen, Denmark. The company has developed Chemetics®, a unique, patent protected hybrid of proven wet chemistry and molecular biology which represents the ultimate fragment based drug discovery technology. Chemetics® enables rapid synthesis and DNA-tagging of hundreds of millions of chemically diverse drug-like small molecule compounds and the efficient screening of these, facilitating the identification of potent drug leads at unprecedented quantity, quality and speed compared to existing drug discovery technologies.
Nuevolutions library collection currently exceeds 1 billion small molecule compounds and synthetic biologics for screening. Nuevolution partners its technology with pharmaceutical and biotechnology companies. Nuevolution has entered into agreements with Merck & Co., Lexicon Pharmaceuticals, GlaxoSmithKline, Novartis Pharma and Boehringer Ingelheim. Nuevolution has also entered into a joint venture consortium between Nuevolution, EpiTherapeutics, ExpreS2ion Biotechnologies and Professor Kristian Helin (Biotech Research & Innovation Centre, University of Copenhagen) aiming at discovery and development of novel small molecule drugs against epigenetic factors. This $4 million budget project is supported by the Danish High Technology Fund. Nuevolution has demonstrated the power of Chemetics® by identifying highly potent and drug like novel ligands with the potential to address major unmet medical needs across a range of therapeutic areas and target classes.
Nuevolution is a privately owned company by key Scandinavian investors, including Industrifonden, SEB Venture Capital, Sunstone Capital, SLS Invest and Novo A/S.
For further details about Nuevolution and the Chemetics® technology please contact:
Thomas Franch, CSO
Phone: +45 7020 0987